| Literature DB >> 27431504 |
Mikael Sonesson1, Emelie De Geer2, Jaqueline Subraian3, Sofia Petrén4.
Abstract
BACKGROUND: Recently low-level laser therapy (LLLT) has been proposed to improve orthodontic treatment. The aims of this systematic review were to investigate the scientific evidence to support applications of LLLT: (a) to accelerate tooth movement, (b) to prevent orthodontic relapse and (c) to modulate acute pain, during treatment with fixed appliances in children and young adults.Entities:
Keywords: Low-level laser therapy; Orthodontics; Pain; Relapse; Tooth movement
Mesh:
Year: 2016 PMID: 27431504 PMCID: PMC4948087 DOI: 10.1186/s12903-016-0242-8
Source DB: PubMed Journal: BMC Oral Health ISSN: 1472-6831 Impact factor: 2.757
Search strategy
| Tooth movement | Orthodontic relapse | Acute pain | |
|---|---|---|---|
| Search block | |||
| #1 | Orthodontics OR Orthodontic OR Fixed Appliance | Orthodontics OR Orthodontic OR Fixed Appliance | Orthodontics OR Orthodontic OR Fixed Appliance |
| #2 | Laser OR Low level laser therapy OR LLLT | Laser OR Low level laser therapy OR LLLT | Laser OR Low level laser therapy OR LLLT |
| #3 | Tooth movement OR Velocity OR Rate OR Speed | Relapse OR Recurrence OR Retention | Pain OR Discomfort |
| #4 | #1 AND #2 AND #3 | #1 AND #2 AND #3 | #1 AND #2 AND #3 |
Inclusion/exclusion criteria
| Tooth movement | Orthodontic relapse | Acute pain | |
|---|---|---|---|
| Inclusion criteria | |||
| Study design | – | RCT, CCT | – |
| Observation period | – | Unlimited | – |
| Language | – | English, Scandinavian | – |
| Population | – | Male/female, mean age 10–30 years, sample size ≥ 20/group | – |
| Intervention | LLLT accelerate movement | LLLT prevent relapse | LLLT diminish acute pain |
| Control | – | Control or placebo | – |
| Outcome | Measurement in mm or per cent | – | Measurement in NRS or VAS |
| Exclusion criteria | |||
| Problem specification | – | Not addressed | – |
| Research | – | Not original (editorial, review etc.), case series | – |
Summary of data of the included studies on tooth movement
| Study | Country | Subjects | Study design | Orthodontic treatment | Placebo/ | Measurement | Results | Type of laser | Wavelength (nm) | Time per point/ | Frequency of laser | Power (mW) | Dose | Time per point/ | Frequency of laser treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Doshi-Meht [ | India | 20/20 | Single blinded | Maxillary and mandibular canine retraction | Placebo | Digital caliper on model | Mean increased tooth movement rate end of 3 month: LG: Maxilla; 54 %. Mandible; 58 % | AlGaAs | 800 | 10 s/1 min 40 s | Day 3, 7, and 14 in the first month. | 0,25 | 5 | 10 s/Unclear | Day 3, 7, and 14 in the first month. Thereafter on every 15th day until complete canine retraction on the experimental side, average 4.5 month. |
| Genc [ | Turkey | 20/20 | Unblinded | Maxillary canine retraction | Control | Digital calliper | Tooth movement LG; 20–40 % faster than C. | GaAlAs | 808 | 10 s/1 min 40 s | Day 0, 3, 7, 14, 21, 28 | 20 | 0,71 | 10 s/1 min 40 s | Day 0, 3, 7, 14, 21, 28 after activation |
| Heravi [ | Iran | 20/20 | Single blinded | Maxillary canine retraction | Control | Computer measurements on photos of study models | No differences between LG and C after 56 days. | GaAlAs | 810 | 30 s/7 min 30 s | Day 4, 7, 11, 15 and 28 in | – | – | – | – |
Summary of data of the included studies on acute pain
| Study | Country | Subjects | Study design | Orthodontic treatment | Placebo/control group | Pain measurement | Results (laser group, LG, laser side, LS, control, C, placebo, P) | Type of laser | Wavelength (nm) | Power (mW) | Time per point/ | Frequency of laser treatment (day, d, week, wk, month, mo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lim [ | Singapore | 39/39 | Double blinded placebo, RCT | Elastomeric separators | Placebo | VAS | No difference in pain sensation | GaAsAl | 830 | 30 | 15, 30, 60 s/ | One session/d during 5 d |
| Harazaki [ | Japan | 20/20/44 | Single blinded | Fixed appliance | Placebo and control | NRS (1–5) | Pain onset later in LG approx. 3 h | HeNe | 632,8 | 6 | 30 s/ | One |
| Harazaki [ | Japan | 20/20 | Single blinded | Fixed appliance | Placebo | NRS (1–5) | LG pain reduction rate: 48.4 % | HeNe | 832.8 | 6 | 30 s/ | One, until pain ceased |
| Fujiyama [ | Japan | 60/60/30 | Single blinded CCT (split mouth) | Elastomeric separators | Control | VAS | Lower VAS separators day 4. VAS: LS 36.1, C 60.1 | CO2 | Not reported | 2000 | 30 s/ | One |
| Tortamano [ | Brazil | 20/20/20 | Double blind RCT | Fixed | Placebo and control | NRS (1–5) | Lower 1th day. LG: 1.95, Placebo: 1.7, C:2.05. ended earlier LG | GaAsAl | 830 | 30 | 16 s/ | One |
| Doshi-Mehta [ | India | 20/20 | Single blinded RCT | Upper, lower canine retraction | Placebo | Children’s VAS | Lower VAS day 3 and 30. Day 3: LG 0.8, C 3.2. Day 30: LG 1.5, C 2.4 | AlGaAs | 800 | 0,7 | 30 s/Unclear | Day 0, 3, 7, 14, every 15th d in 4.5 mo. |
| Kim [ | Korea | 28/30/30 | Single blinded RCT | Elastomeric separators | Placebo and control | VAS | LG lower VAS up to day 1. Overall mean VAS: LG:19.7, C:35.64 | AlGaInP | 635 | 6 | 30 s/ | 2 times/d for 1 wk |
| Artés-Ribas [ | Spain | 20/20 | Single blinded RCT (split mouth) | Elastomeric separators | Placebo | VAS | Overall mean VAS LG: 7.7, C:14.1 | GaAlAs | 830 | 100 | 20 s/ | One |
| Domínguez [ | Colombia | 60/60 | Single blinded RCT (split mouth) | Fixed appliance | Placebo | VAS | Lower max pain on VAS. | GaAlAs | 830 | 100 | 22 s/44 s | One |
| Eslamían [ | Iran | 37/37 | Single blinded RCT (split mouth) | Elastomeric separators | Placebo | VAS | Lower VAS 6 h, 24 h, 30 h, day 3. VAS: LG:0.86, PG:1.10 | AlGaAs | 810 | 100 | 20 s/ | Two |
| Nóbrega [ | Brazil | 30/30 | Double blinded RCT | Elastomeric separators | Placebo | VAS | LG Lower VAS | AlGaAS | 830 | 40,6 | 25–50 s/ | One |
| Abtahi [ | Iran | 29/29 | Single blinded RCT (split mouth) | Elastomeric separators | Placebo | VAS | Lower VAS day 2 | GaAs | 904 | 200 | 7.5 s/30 s | One session/d, |
| Heravi [ | Iran | 20/20 | Single blinded | Maxillary canine retraction | Control | – | No differences between groups after 56 days | GaAlAs | 810 | 200 | 30 s/ | Day 4, 7, 11, 15, 28 1th mo.. Day 32, 25, 39, 43, 56 2nd mo. |
Quality template, modified version from The Swedish Council on Technology Assessment in Health Care, SBU
| A1. Review of shortcomings – any systematic errors (bias) | Yes | No | Indefinite | Not applicable |
|---|---|---|---|---|
| A1. Selection bias | ||||
| a) Was an appropriate method for randomizing used? | – | – | – | – |
| b) If the study used any form of limitation within the process of randomizing (for example block, strata, minimizing), are the reasons for this adequate? | – | – | – | – |
| c) Was the composition of the groups adequately analogous? | – | – | – | – |
| d) If there was any correction for imbalances in the baseline variables, was it performed in an adequate way? | – | – | – | – |
|
| ||||
| Concluding assessment: | Low: | Medium: | High: | |
| A2. Treatment bias | ||||
| a) Were the study participants blinded? | – | – | – | – |
| b) Were the researchers blinded? | – | – | – | – |
|
| ||||
| Concluding assessment: | Low: | Medium: | High: | |
| A3. Assessment bias | ||||
| a) Were the observers evaluating the results blinded to the type of intervention? | – | – | – | – |
| b) Were the observers reviewing the outcome impartial? | – | – | – | – |
| c) Was the outcome adequately defined? | – | – | – | – |
| d) Was the outcome identified/diagnosed with a validated method of measurement? | – | – | – | – |
| e) Were adequate statistical methods applied to reporting the outcome? | – | – | – | – |
|
| ||||
| Concluding assessment: | Low: | Medium | High: | |
| A4. Failure bias | ||||
| a) Was the statistical handling of attrition adequate? | – | – | – | – |
| b) Were the reasons for attrition analysed? | – | – | – | – |
|
| ||||
| Concluding assessment: | Low: | Medium: | High: | |
| A5. Reporting bias | ||||
| a) Were side effects/complications measured in a systematic manner? | – | – | – | – |
|
| ||||
| Concluding assessment: | Low: | Medium: | High: | |
| A6. Conflicts of interest | ||||
| a) Was there a risk of conflicts of interest or of influence from a financier? | – | – | – | – |
|
| ||||
| Concluding assessment: | Low: | Medium: | High: | |
| A7. Study population | ||||
| a) Was the population from which the participants were sampled described and relevant? | – | – | – | – |
| b) Was the recruitment of participants acceptable? | – | – | – | – |
| c) Was the study population adequate? | – | – | – | – |
| d) Was the analysed population (ITT or PP) appropriate to the question to be addressed by the study? | – | – | – | – |
|
| ||||
| Concluding assessment: | Low: | Medium: | High: | |
| Appraisal | ||||
| A1. Selection bias | – | – | – | – |
| A2. Treatment bias | – | – | – | – |
| A3. Assessment bias | – | – | – | – |
| A4. Failure bias | – | – | – | – |
| A5. Reporting bias | – | – | – | – |
| A6. Conflicts of interest bias | – | – | – | – |
| A7. Study population | – | – | – | – |
|
| ||||
| Concluding assessment of quality: | Low: | Medium: | High: | |
Fig. 1Flowchart showing studies included in LLLT and acceleration of tooth movement. a Identification. b Screening. c Eligibility. d Included
Fig. 2Flowchart showing studies included in LLLT and prevention of orthodontic relapse. a Identification. b Screening. c Eligibility. d Included
Fig. 3Flowchart showing studies included in LLLT and modulation of acute pain. a Identification. b Screening. c Eligibility. d Included
Quality evaluation protocol showing total score for studies on tooth movement
| Study | Adequate selection | Single blinded | Adequate assessment of result | Adequate report ofattrition | Adequate report of side effects | No conflict of interests | Adequate study population | TOTAL |
|---|---|---|---|---|---|---|---|---|
| Doshi-Mehta [ | Yes | Yes | Yes | Not reported | No | Not reported | Yes | Moderate |
| Genc [ | Yes | No | Yes | Not reported | No | Not reported | Yes | Moderate |
| Heravi [ | Yes | Yes | Yes | Not reported | No | Not reported | Yes | Moderate |
Quality of evidence that LLLT accelerates tooth movement and modulate acute pain
| Accelerating tooth movement | Modulation of acute pain | |
|---|---|---|
|
| 3 | 13 |
|
| 60 | 333 |
|
| RCT, CCT | RCT |
|
| ⊕ ⊕ ⊕ | ⊕ ⊕ ⊕⊕ |
|
| 1 | 1 |
|
| 0 | 1 |
|
| 1 | 0 |
|
| 0 | 0 |
|
| 0 | 0 |
|
| 0 | 0 |
|
| 0 | 0 |
|
| 0 | 0 |
|
| ⊕ Very low | ⊕⊕ Low |
Factors that can reduce the quality of the evidence (1 or 2 levels)
Factor that can reduce the quality of the evidence (1 level)
Factor that can increase the quality of the evidence (1 or 2 levels)
Factors that can increase the quality of the evidence (1 level)
Quality evaluation protocol showing total score for studies on acute pain
| Study | Adequate selection | Single blinded | Double blinded | Adequate assessment of result | Adequate report of attrition | Adequate report of side effects | No conflict of interests | Adequate study population | TOTAL |
|---|---|---|---|---|---|---|---|---|---|
| Lim [ | Yes | No | Yes | Yes | Not reported | No | Not reported | No | Moderate |
| Harazki [ | No | Yes | No | No | Not reported | No | Not reported | Yes | Low |
| Harazaki [ | No (CCT) | Yes | No | No | Not reported | No | Not reported | Yes | Low |
| Fujiyama [ | No (CCT) | Yes | No | Yes | Not reported | No | Not reported | Yes | Moderate |
| Tortamano [ | Yes | No | Yes | Yes | Not reported | No | Not reported | Yes | Moderate |
| Doshi-Metha [ | Yes | Yes | No | Yes | Not reported | No | Not reported | Yes | Moderate |
| Kim [ | Yes | Yes | No | Yes | Not reported | No | Not reported | Yes | Moderate |
| Artés-Ribas [ | Yes | Yes | No | Yes | Not reported | No | Not reported | Yes | Moderate |
| Dominguez [ | Yes | Yes | No | Yes | Not reported | No | Yes | Yes | Moderate |
| Eslamian [ | Yes | Yes | No | Yes | Not reported | No | Not reported | Yes | Moderate |
| Nóbrega [ | Yes | No | Yes | Yes | Yes | No | Yes | Yes | High |
| Abtahi [ | Yes | Yes | No | Yes | Not reported | No | Yes | No | Moderate |
| Heravi [ | Yes | Yes | No | Yes | Not reported | No | Not reported | Yes | Moderate |